Investors Hangout Stock Message Boards Logo
  • Mailbox
  • Favorites
  • Boards
    • The Hangout
    • NASDAQ
    • NYSE
    • OTC Markets
    • All Boards
  • Whats Hot!
    • Recent Activity
    • Most Viewed Boards
    • Most Viewed Posts
    • Most Posted
    • Most Followed
    • Top Boards
    • Newest Boards
    • Newest Members
  • Blog
    • Recent Blog Posts
    • Recently Updated
    • News
    • Stocks
    • Crypto
    • Investing
    • Business
    • Markets
    • Economy
    • Real Estate
    • Personal Finance
  • Market Movers
  • Interactive Charts
  • Login - Join Now FREE!
  1. Home ›
  2. Stock Message Boards ›
  3. Stock Boards ›
  4. Durect Corp. (DRRX) Message Board

What is DUR-928 and The Benefits of Fast Track Designation

Message Board Public Reply | Private Reply | Keep | Replies (0)                   Post New Msg
Edit Msg () | Previous | Next


Post# of 70
(Total Views: 227)
Posted On: 05/05/2024 11:49:24 PM
Posted By: MythicSphinx35
DUR-928, also known as larsucosterol, is an investigational drug being developed by DURECT Corporation (DRRX) for the treatment of Alcoholic Hepatitis (AH) and it has received Fast Track designation from the FDA.

How Epigenetics Plays a Role:
DUR-928 is believed to work through epigenetics. Epigenetics refers to changes in gene expression that don't involve alterations in the DNA sequence itself. These changes can influence how cells function.

Here's a simplified explanation of how DUR-928 might work:
In AH, the liver becomes inflamed and damaged due to excessive alcohol consumption. This damage disrupts epigenetic processes, leading to abnormal gene expression and contributing to liver dysfunction. DUR-928 may help restore normal epigenetic patterns in liver cells, promoting healthy gene expression and potentially facilitating liver repair.

Importance of FDA Fast Track Designation:
The FDA Fast Track designation is designed to expedite the development and review of drugs that address serious or life-threatening conditions and have the potential to fill an unmet medical need. DUR-928, has received Fast Track designation from the FDA.

U.S. Market Size: Approx. 150,000 patients are hospitalized annually with AH. Currently there is a very high mortality rate associated with AH (30% at 90 days approx.). It is estimated that DUR-928 if approved may have the potential to generate $1B in annual sales.


(1)
(0)




Durect Corp. (DRRX) Stock Research Links


  1.  
  2.  


  3.  
  4.  
  5.  






Investors Hangout

Home

Mailbox

Message Boards

Favorites

Whats Hot

Blog

Settings

Privacy Policy

Terms and Conditions

Disclaimer

Contact Us

Whats Hot

Recent Activity

Most Viewed Boards

Most Viewed Posts

Most Posted Boards

Most Followed

Top Boards

Newest Boards

Newest Members

Investors Hangout Message Boards

Welcome To Investors Hangout

Stock Message Boards

American Stock Exchange (AMEX)

NASDAQ Stock Exchange (NASDAQ)

New York Stock Exchange (NYSE)

Penny Stocks - (OTC)

User Boards

The Hangout

Private

Global Markets

Australian Securities Exchange (ASX)

Euronext Amsterdam (AMS)

Euronext Brussels (BRU)

Euronext Lisbon (LIS)

Euronext Paris (PAR)

Foreign Exchange (FOREX)

Hong Kong Stock Exchange (HKEX)

London Stock Exchange (LSE)

Milan Stock Exchange (MLSE)

New Zealand Exchange (NZX)

Singapore Stock Exchange (SGX)

Toronto Stock Exchange (TSX)

Contact Investors Hangout

Email Us

Follow Investors Hangout

Twitter

YouTube

Facebook

Market Data powered by QuoteMedia. Copyright © 2025. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges).
Analyst Ratings & Earnings by Zacks. RT=Real-Time, EOD=End of Day, PD=Previous Day. Terms of Use.

© 2025 Copyright Investors Hangout, LLC All Rights Reserved.

Privacy Policy |Do Not Sell My Information | Terms & Conditions | Disclaimer | Help | Contact Us